This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -15.65% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSMD
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
by Zacks Equity Research
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -45.22% and 7.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
by Zacks Equity Research
Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD